Xuan Zhang
zhangxuan@simm.ac.cn
Chinese, English
Shanghai
University of Chinese Academy of Sciences
Medical School
  • 2009-09 to 2014-05 PhD: East China Normal University
  • 2001-09 to 2005-06 Bachelor's Degree: Shanghai Normal University
  • 2019-07 to 2020-12 - University of Florida - Research Assistant Professor
  • 2018-06 to 2019-07 - University of Florida - Postdoctoral Researcher
  • 2014-12 to 2018-05 - University of Arkansas for Medical Sciences - Postdoctoral Researcher
  • 2014-08 to 2014-11 - East China Normal University - Research Assistant
  • 2005-07 to 2009-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Research Assistant
Design and biological research of protein degraders
  • A rationally designed fluorescence probe achieves highly specific and long-term detection of senescence in vitro and in vivo., Li Hu, Chanjuan Dong, Zhe Wang, Shengyuan He, Yiwen Yang, Meiting Zi, Huiqin Li, Yanghuan Zhang, Chuanjie Chen, Runzi Zheng, Shuting Jia, Jing Liu, Xuan Zhang, Yonghan He, 2023
  • Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity., Chuanjie Chen, Yiwen Yang, Zhe Wang, Huiwen Li, Chanjuan Dong, Xuan Zhang, 2023
  • Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells., Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, MyungChul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, YangXin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang, 2021
  • Concise Synthesis of (S)-δ-CEHC,a Metabolite of Vitamin E., Matthew Burke, Pratik Pal, Peiyi Zhang, Xuan Zhang, Guangrong Zheng, 2021
  • Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity., He, Yonghan, Li, Wen, Lv, Dongwen, Zhang, Xin, Zhang, Xuan, Ortiz, Yuma T, Budamagunta, Vivekananda, Campisi, Judith, Zheng, Guangrong, Zhou, Daohong, 2020
  • Recent advances in small molecular modulators targeting histone deacetylase 6., Xiao, Yufeng, Zhang, Xuan, 2020
  • Assays and technologies for developing proteolysis targeting chimera degraders., Liu, Xingui, Zhang, Xuan, Lv, Dongwen, Yuan, Yaxia, Zheng, Guangrong, Zhou, Daohong, 2020
  • Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity., Yonghan He, Xuan Zhang, Jianhui Chang, HaNeui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dongwen Lv, Lin Song, Wen Li, Dinesh Thummuri, Yaxia Yuan, Janet S Wiegand, Yuma T Ortiz, Vivekananda Budamagunta, Jennifer H Elisseeff, Judith Campisi, Maria Almeida, Guangrong Zheng, Daohong Zhou, 2020
  • Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production., Xingui Liu, Zhengya Gao, Qiang Fu, Lin Song, Peiyi Zhang, Xuan Zhang, Howard Hendrickson, Peter A Crooks, Daohong Zhou, Guangrong Zheng, 2020
  • PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors., Peiyi Zhang, Xuan Zhang, Xingui Liu, Sajid Khan, Daohong Zhou, Guangrong Zheng, 2020
  • PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics., Khan, Sajid, He, Yonghan, Zhang, Xuan, Yuan, Yaxia, Pu, Shaoyan, Kong, Qingpeng, Zheng, Guangrong, Zhou, Daohong, 2020
  • Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine-Substituted delta-Tocotrienol Derivative., Liu, Xingui, Poddar, Saikat, Song, Lin, Hendrickson, Howard, Zhang, Xuan, Yuan, Yaxia, Zhou, Daohong, Zheng, Guangrong, 2020
  • DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas., He, Yonghan, Koch, Raphael, Budamagunta, Vivekananda, Zhang, Peiyi, Zhang, Xuan, Khan, Sajid, Thummuri, Dinesh, Ortiz, Yuma T, Zhang, Xin, Lv, Dongwen, Wiegand, Janet S, Li, Wen, Palmer, Adam C, Zheng, Guangrong, Weinstock, David M, Zhou, Daohong, 2020
  • Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies., He, Yonghan, Khan, Sajid, Huo, Zhiguang, Lv, Dongwen, Zhang, Xuan, Liu, Xingui, Yuan, Yaxia, Hromas, Robert, Xu, Mingjiang, Zheng, Guangrong, Zhou, Daohong, 2020
  • Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs., Xiao, Yufeng, Wang, Jia, Zhao, Lisa Y, Chen, Xinyi, Zheng, Guangrong, Zhang, Xuan, Liao, Daiqing, 2020
  • Discovery of PROTAC BCL-X-L degraders as potent anticancer agents with low on-target platelet toxicity., Zhang, Xuan, Thummuri, Dinesh, Liu, Xingui, Hu, Wanyi, Zhang, Peiyi, Khan, Sajid, Yuan, Yaxia, Zhou, Daohong, Zheng, Guangrong, 2020
  • Discovery of IAP-recruiting BCL-X-L PROTACs as potent degraders across multiple cancer cell lines., Zhang, Xuan, He, Yonghan, Zhang, Peiyi, Budamagunta, Vivekananda, Lv, Dongwen, Thummuri, Dinesh, Yang, Yang, Pei, Jing, Yuan, Yaxia, Zhou, Daohong, Zheng, Guangrong, 2020
  • Targeting anti-apoptotic BCL-2 family proteins for cancer treatment., Zhang, Xuan, Liu, Xingui, Zhou, Daohong, Zheng, Guangrong, 2020
  • Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL., Xuan Zhang, Dinesh Thummuri, Yonghan He, Xingui Liu, Peiyi Zhang, Daohong Zhou, Guangrong Zheng, 2019
  • A selective BCL-X-L PROTAC degrader achieves safe and potent antitumor activity., Khan, Sajid, Zhang, Xuan, Lv, Dongwen, Zhang, Qi, He, Yonghan, Zhang, Peiyi, Liu, Xingui, Thummuri, Dinesh, Yuan, Yaxia, Wiegand, Janet S, Pei, Jing, Zhang, Weizhou, Sharma, Abhisheak, McCurdy, Christopher R, Kuruvilla, Vinitha M, Baran, Natalia, Ferrando, Adolfo A, Kim, Yongmi, Rogojina, Anna, Houghton, Peter J, Huang, Guangcun, Hromas, Robert, Konopleva, Marina, Zheng, Guangrong, Zhou, Daohong, 2019
  • A near-infrared fluorescent probe for rapid detection of hydrogen peroxide in living cells., Zhang, Xuan, Zhang, Lun, Liu, Yaqian, Bao, Bin, Zang, Yi, Li, Jia, Lu, Wei, 2015
  • Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors., Zhang, Xuan, Kong, Yannan, Zhang, Jie, Su, Mingbo, Zhou, Yubo, Zang, Yi, Li, Jia, Chen, Yi, Fang, Yanfen, Zhang, Xiongwen, Lu, Wei, 2015
  • Design, synthesis and biological evaluation of C(6)-indole celastrol derivatives as potential antitumor agents., Tang, Kaiyong, Huang, Jinwen, Pan, Junfang, Zhang, Xuan, Lu, Wei, 2015
  • NIR absorbing DICPO derivatives applied to wide range of pH and detection of glutathione in tumor., Bao, Bin, Liu, Meng, Liu, Yaqian, Zhang, Xuan, Zang, Yi, Li, Jia, Lu, Wei, 2015
  • Design, synthesis, and biological evaluation of a new class of MT2-selective agonists., Zhang, Xuan, Wang, Zhilong, Huang, Qingqing, Luo, Yu, Xie, Xin, Lu, Wei, 2014
  • Design, synthesis and biological evaluation of 4 '-demethyl-4-deoxypodophyllotoxin derivatives as novel tubulin and histone deacetylase dual inhibitors., Zhang, Xuan, Zhang, Jie, Su, Mingbo, Zhou, Yubo, Chen, Yi, Li, Jia, Lu, Wei, 2014
  • The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors., Zhang, Xuan, Su, Mingbo, Chen, Yi, Li, Jia, Lu, Wei, 2013
  • The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase., Zhang, Xuan, Bao, Bin, Yu, Xiuhua, Tong, Linjiang, Luo, Yu, Huang, Qingqing, Su, Mingbo, Sheng, Li, Li, Jia, Zhu, Hong, Yang, Bo, Zhang, Xiongwen, Chen, Yi, Lu, Wei, 2013
  • Synthesis and bioassay of beta-(1,4)-D-mannans as potential agents against Alzheimer's disease., Jiang, Ruwei, Du, Xiaoguang, Zhang, Xuan, Wang, Xin, Hu, Dingyu, Meng, Tao, Chen, Yuelei, Geng, Meiyu, Shen, Jingkang, 2013
  • The discovery of colchicine-SAHA hybrids as a new class of antitumor agents., Zhang, Xuan, Zhang, Jie, Tong, Linjiang, Luo, Yu, Su, Mingbo, Zang, Yi, Li, Jia, Lu, Wei, Chen, Yi, 2013
  • STEREOSELECTIVE SYNTHESIS OF MELATONIN RECEPTOR AGONIST RAMELTEON VIA ASYMMETRIC MICHAEL ADDITION., Zhang, Xuan, Yuan, Wei, Luo
Protein Degraders Biological Research Drug Design Pharmaceutical Chemistry Targeted Therapy Proteolysis-Targeting Chimeras Cancer Treatment Molecular Biology Biochemistry Pharmacology

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.